ALK and neoplasm: Mechanistically, brigatinib exhibits selective binding affinity towards the ATP-binding domain of the ALK receptor tyrosine kinase, thereby inducing inhibition of ALK-mediated signaling pathways, consequently resulting in the demise of tumor cells.